文献速递呼吸道感染呼吸危重症与机械通气

COVID-19机械通气患者的细菌重叠感染肺炎

Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该单中心观察性研究分析了179例需机械通气的SARS-CoV-2肺炎患者,发现插管48小时内细菌重叠感染率为21%,44.4%患者发生至少一次呼吸机相关肺炎(VAP)。基于支气管肺泡灌洗液的管理较指南推荐显著减少抗生素使用,而临床标准无法区分有无细菌重叠感染。

要点

  • 插管48小时内细菌重叠感染率21%,指南经验性抗生素导致过度使用。
  • 44.4%患者发生VAP,其中20.8%初始VAP由难治性病原体引起。
  • 临床标准无法准确识别细菌重叠感染,需依赖BAL液微生物分析。

核心结论

  • SARS-CoV-2肺炎机械通气患者插管时细菌重叠感染率低于25%,指南经验性抗生素管理导致过度使用。
  • 44%患者发生细菌性VAP,缺乏BAL液微生物分析时无法准确识别。

研究设计与样本

  • 单中心观察性研究,分析179例需机械通气的SARS-CoV-2肺炎患者的386份支气管镜BAL液样本,采用定量培养和多重PCR panel。

主要发现

  • 插管48小时内细菌重叠感染检测率为21%。
  • 15例(20.8%)初始VAP由难治性病原体引起。
  • 临床标准无法区分有无细菌重叠感染。
  • 基于BAL的管理较指南推荐显著减少抗生素使用。

关键数值与推荐

  • 细菌重叠感染定义为插管48小时内检测到,发生率21%。
  • VAP发生率45.2/1000机械通气日,44.4%患者发生至少一次VAP。
  • 难治性病原体占初始VAP的20.8%。

临床怎么用

  • 对SARS-CoV-2肺炎机械通气患者,插管时不应仅凭临床标准常规经验性使用抗生素。
  • 基于BAL液微生物分析的管理可减少抗生素过度使用。

局限性

  • 单中心观察性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Current guidelines recommend patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia receive empirical antibiotics for suspected bacterial superinfection on the basis of weak evidence. Rates of ventilator-associated pneumonia (VAP) in clinical trials of patients with SARS-CoV-2 pneumonia are unexpectedly low. Objectives: We conducted an observational single-center study to determine the prevalence and etiology of bacterial superinfection at the time of initial intubation and the incidence and etiology of subsequent bacterial VAP in patients with severe SARS-CoV-2 pneumonia. Methods: Bronchoscopic BAL fluid samples from all patients with SARS-CoV-2 pneumonia requiring mechanical ventilation were analyzed using quantitative cultures and a multiplex PCR panel. Actual antibiotic use was compared with guideline-recommended therapy. Measurements and Main Results: We analyzed 386 BAL samples from 179 patients with SARS-CoV-2 pneumonia requiring mechanical ventilation. Bacterial superinfection within 48 hours of intubation was detected in 21% of patients. Seventy-two patients (44.4%) developed at least one VAP episode (VAP incidence rate = 45.2/1,000 ventilator days); 15 (20.8%) initial VAPs were caused by difficult-to-treat pathogens. The clinical criteria did not distinguish between patients with or without bacterial superinfection. BAL-based management was associated with significantly reduced antibiotic use compared with guideline recommendations. Conclusions: In patients with SARS-CoV-2 pneumonia requiring mechanical ventilation, bacterial superinfection at the time of intubation occurs in <25% of patients. Guideline-based empirical antibiotic management at the time of intubation results in antibiotic overuse. Bacterial VAP developed in 44% of patients and could not be accurately identified in the absence of microbiologic analysis of BAL fluid.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Pickens CO, Gao CA, Cuttica MJ, et al. Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. Am J Respir Crit Care Med. 2021. PMID: 34409924. doi:10.1164/rccm.202106-1354OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。